Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

NCT06216392 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: GR1802 injection
BIOLOGICAL: placebo

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.